Business Wire

CALLDORADO

8.9.2021 11:29:08 CEST | Business Wire | Press release

Share
Calldorado Buys User Acquisition Specialist Appvestor

Calldorado has acquired longstanding partner Appvestor in a deal that will give its community of app developers instant access to advanced user acquisition tools.

The two companies make a good fit. Both are dedicated to helping app makers grow but in different ways. Calldorado’s unique technology helps Android developers keep existing user bases active and monetize them. Meanwhile, Appvestor’s AI-powered tools help them find new customers.

Appvestor was established in 2017 to build a technology engine that deploys machine learning and predictive algorithms to establish the best destinations for paid marketing campaigns. Its complete service to developers includes:

  • A technology engine that maps campaign progress against revenue, conversion, and retention at a user level.
  • Experience in running marketing campaigns that deliver large volumes of new users and the highest return on investment.
  • Access to creative resources including studio and production.
  • Expertise in ASO (App Store Optimization), which boosts the impact of campaigns and the number of customer conversions.

Calldorado has been working closely with Appvestor since its launch. Mathias Schroeder, co-CEO and co-founder of Calldorado, believes the buy-out is a logical move for both parties. He says: “Our tech does a brilliant job of keeping app users engaged. But it doesn’t find new ones. That’s why we have worked with many user acquisition platforms in the past.

"Appvestor was always the best. It’s the only one with predictive algorithms that can dynamically adjust a marketing campaign to maximize return on investment at all times. Paid user acquisition is a key strategic asset for us, so acquiring Appvestor makes perfect sense. We can’t wait to combine the two companies’ skills into a service that can really help scale our first-party and customer apps.”

The acquisition comes at a time of rapid growth in the app market. Total app downloads across both iOS and Google Play hit 130 billion (1 ). This was a 10% increase on 2019.

Meanwhile, total consumer spend on apps (in-app purchases, subscriptions, and premium apps) reached $143 billion in 2020 – up 20% in a year. App Annie believes the total could hit $270 billion by 2025.

The buoyant app market has fuelled a fast-growing app install ad sector. Developers increasingly rely on paid marketing to drive installs. So much so that analysts expect the total spend to rise from $57.8 billion in 2019 to $118 billion in 2022 (2).

About Calldorado

Calldorado’s unique user activation and monetization technology, the Caller SDK, helps Android app publishers keep their app user bases active, drives incremental traffic, and maximizes app revenue. Calldorado also publishes first-party apps; it launched its own content business with the acquisition of CIAmedia in 2018. A year later it acquired the call enrichment specialist adaffix. Calldorado was established in 2016 with headquarters in Denmark and is privately held.

1. Source: App Annie – State of Mobile 2021 https://www.appannie.com/en/go/state-of-mobile-2021/

2. Source: Appsflyer https://www.appsflyer.com/blog/trends-insights/app-install-ad-spend/

Link:

ClickThru

Social Media:

https://www.facebook.com/calldorado

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye